Thrombophilia due to activated protein C resistance
MONDO:0008560A hemostatic disorder characterized by a poor anticoagulant response to activated protein C (APC). The activated form of Factor V (Factor Va) is more slowly degraded by activated protein C. Factor V Leiden mutation (R506Q) is the most common cause of APC resistance.
Also known as: thrombophilia 2 due to activated protein C resistance, thrombophilia due to activated protein C resistance, APC resistance, Activated Protein C resistance, Pccf deficiency, Proc cofactor deficiency, THPH2, resistance, APC
45 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Can extra care after transplant help older patients live better?
Disease control TerminatedThis study tested two extra care programs—supportive palliative care and clinical management of other health issues—for older or frail patients who had a donor stem cell transplant. The goal was to see if these programs could improve quality of life and survival compared to stand…
Phase: PHASE2, PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Cancer drug combo shows promise for Hard-to-Treat bowel cancer
Disease control TerminatedThis study tested a combination of two drugs, atezolizumab and bevacizumab, in 46 people with advanced colorectal cancer that had stopped responding to chemotherapy and had a specific genetic feature called MSI-like. The goal was to see if the treatment could shrink tumors. The s…
Phase: PHASE2 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC